{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T12:02:42Z","timestamp":1764331362040,"version":"3.46.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"DOI":"10.1186\/s13256-025-05660-x","type":"journal-article","created":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T11:58:02Z","timestamp":1764331082000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Analysis of different prognoses in two hepatocellular carcinoma patients with pathological complete response after conversion therapy: a case report"],"prefix":"10.1186","volume":"19","author":[{"given":"Qinliang","family":"Fang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yibin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fuqiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenyu","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianyin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,28]]},"reference":[{"issue":"2","key":"5660_CR1","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1002\/hep.29498","volume":"67","author":"C Valery","year":"2018","unstructured":"Valery C, et al. Projections of primary liver cancer to 2030 in 30 countries worldwide. Hepatology. 2018;67(2):600\u201311.","journal-title":"Hepatology"},{"issue":"3","key":"5660_CR2","doi-asserted-by":"publisher","first-page":"155","DOI":"10.5582\/bst.2021.01091","volume":"15","author":"H Zhou","year":"2021","unstructured":"Zhou H, Song T. Conversion therapy and maintenance therapy for primary hepatocellular carcinoma. Biosci Trends. 2021;15(3):155\u201360.","journal-title":"Biosci Trends"},{"issue":"15","key":"5660_CR3","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1200\/JCO.23.02745","volume":"42","author":"JD Gordan","year":"2024","unstructured":"Gordan JD, et al. Systemic therapy for advanced hepatocellular carcinoma: ASCO guideline update. J Clin Oncol. 2024;42(15):1830\u201350.","journal-title":"J Clin Oncol"},{"issue":"2","key":"5660_CR4","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.jhep.2024.08.028","volume":"82","author":"European Association for the Study of the, L.","year":"2025","unstructured":"European Association for the Study of the, L. EASL clinical practice guidelines on the management of hepatocellular carcinoma. J Hepatol. 2025;82(2):315\u201374.","journal-title":"J Hepatol"},{"issue":"5","key":"5660_CR5","doi-asserted-by":"publisher","first-page":"541","DOI":"10.6004\/jnccn.2021.0022","volume":"19","author":"AB Benson","year":"2021","unstructured":"Benson AB, et al. Hepatobiliary cancers, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2021;19(5):541\u201365.","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"5660_CR6","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1186\/s12885-024-13340-0","volume":"24","author":"C Chai","year":"2024","unstructured":"Chai C, et al. Establishment and characterization of a new intestinal-type ampullary carcinoma cell line, DPC-X3. BMC Cancer. 2024;24(1):1558.","journal-title":"BMC Cancer"},{"issue":"7","key":"5660_CR7","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1111\/cas.16194","volume":"115","author":"MD Wang","year":"2024","unstructured":"Wang MD, et al. Conversion therapy for advanced hepatocellular carcinoma in the era of precision medicine: current status, challenges and opportunities. Cancer Sci. 2024;115(7):2159\u201369.","journal-title":"Cancer Sci"},{"key":"5660_CR8","doi-asserted-by":"publisher","DOI":"10.1159\/000545545","author":"Z Pan","year":"2025","unstructured":"Pan Z, et al. Comparison of efficacy between Lenvatinib and bevacizumab in combination of immune checkpoint inhibitor and interventional triple therapy in Chinese advanced hepatocellular carcinoma: the CLEAP 2302 study. Liver Cancer. 2025. https:\/\/doi.org\/10.1159\/000545545.","journal-title":"Liver Cancer"},{"issue":"3","key":"5660_CR9","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1158\/1078-0432.CCR-08-1608","volume":"15","author":"Q Gao","year":"2009","unstructured":"Gao Q, et al. Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma. Clin Cancer Res. 2009;15(3):971\u20139.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"5660_CR10","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/S1470-2045(20)30011-5","volume":"21","author":"S Qin","year":"2020","unstructured":"Qin S, et al. Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial. Lancet Oncol. 2020;21(4):571\u201380.","journal-title":"Lancet Oncol"},{"issue":"7","key":"5660_CR11","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1007\/s00432-006-0091-y","volume":"132","author":"HC Sun","year":"2006","unstructured":"Sun HC, et al. Postoperative interferon alpha treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma: a randomized clinical trial. J Cancer Res Clin Oncol. 2006;132(7):458\u201365.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"5660_CR12","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s10238-025-01698-9","volume":"25","author":"Y Jiang","year":"2025","unstructured":"Jiang Y, et al. Navigating the complexities: challenges and opportunities in conversion therapy for advanced hepatocellular carcinoma. Clin Exp Med. 2025;25(1):169.","journal-title":"Clin Exp Med"},{"issue":"12","key":"5660_CR13","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1111\/liv.12857","volume":"35","author":"WH Wang","year":"2015","unstructured":"Wang WH, et al. Survival benefit with IMRT following narrow-margin hepatectomy in patients with hepatocellular carcinoma close to major vessels. Liver Int. 2015;35(12):2603\u201310.","journal-title":"Liver Int"},{"issue":"2","key":"5660_CR14","first-page":"197","volume":"125","author":"XJ Shi","year":"2012","unstructured":"Shi XJ, et al. Effect of resection following downstaging of unresectable hepatocelluar carcinoma by transcatheter arterial chemoembolization. Chin Med J (Engl). 2012;125(2):197\u2013202.","journal-title":"Chin Med J (Engl)"},{"issue":"5","key":"5660_CR15","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1097\/JS9.0000000000001155","volume":"110","author":"B Li","year":"2024","unstructured":"Li B, et al. Watch-and-wait strategy vs. resection in patients with radiologic complete response after conversion therapy for initially unresectable hepatocellular carcinoma: a propensity score-matching comparative study. Int J Surg. 2024;110(5):2545\u201355.","journal-title":"Int J Surg"},{"issue":"3","key":"5660_CR16","doi-asserted-by":"publisher","first-page":"409","DOI":"10.5009\/gnl16001","volume":"11","author":"SO Jeong","year":"2017","unstructured":"Jeong SO, et al. Predictive factors for complete response and recurrence after transarterial chemoembolization in hepatocellular carcinoma. Gut Liver. 2017;11(3):409\u201316.","journal-title":"Gut Liver"},{"issue":"39","key":"5660_CR17","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000022428","volume":"99","author":"T Liu","year":"2020","unstructured":"Liu T, et al. Risk of primary liver cancer associated with gallstones and cholecystectomy: a competing risks analysis. Medicine (Baltimore). 2020;99(39): e22428.","journal-title":"Medicine (Baltimore)"},{"issue":"11","key":"5660_CR18","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.12998\/wjcc.v12.i11.1881","volume":"12","author":"GSK Jagirdhar","year":"2024","unstructured":"Jagirdhar GSK, Bains Y, Surani S. Removal of intrahepatic bile duct stone could reduce the risk of cholangiocarcinoma. World J Clin Cases. 2024;12(11):1881\u20134.","journal-title":"World J Clin Cases"},{"issue":"1 Pt B","key":"5660_CR19","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.amjsurg.2022.01.008","volume":"224","author":"RY Guan","year":"2022","unstructured":"Guan RY, et al. Antiviral therapy improves postoperative survival of patients with HBV-related hepatocellular carcinoma. Am J Surg. 2022;224(1 Pt B):494\u2013500.","journal-title":"Am J Surg"},{"issue":"1","key":"5660_CR20","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s13027-022-00468-6","volume":"17","author":"Z Li","year":"2022","unstructured":"Li Z, et al. Early and late recurrence after hepatectomy in patients with low-level HBV-DNA hepatocellular carcinoma under antiviral therapy. Infect Agent Cancer. 2022;17(1):56.","journal-title":"Infect Agent Cancer"},{"issue":"5","key":"5660_CR21","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.1245\/s10434-022-12530-z","volume":"30","author":"XD Zhu","year":"2023","unstructured":"Zhu XD, et al. Hepatectomy after conversion therapy using tyrosine kinase inhibitors plus anti-PD-1 antibody therapy for patients with unresectable hepatocellular carcinoma. Ann Surg Oncol. 2023;30(5):2782\u201390.","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"5660_CR22","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1186\/s12876-024-03457-8","volume":"24","author":"Z Chang","year":"2024","unstructured":"Chang Z, et al. Clinical study on conversion therapy of hepatocellular carcinoma - summary and comparison of clinical data from a single center of consecutive four years. BMC Gastroenterol. 2024;24(1):369.","journal-title":"BMC Gastroenterol"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-025-05660-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13256-025-05660-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-025-05660-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T11:58:03Z","timestamp":1764331083000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-025-05660-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,28]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5660"],"URL":"https:\/\/doi.org\/10.1186\/s13256-025-05660-x","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,28]]},"assertion":[{"value":"5 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted according to the ethical standards of the Declaration of Helsinki and approved by the Xiamen University Zhongshan Hospital Medical Ethics Council for Researchers (approval no. xmzsyyky2021-130). Patient 1 provided informed consent to publish their case details and any accompanying images. At the time of writing the case report, patient 2 had already passed away. Written consent for the publication of the case details was provided by the patient\u2019s wife, who provided permission on behalf of the deceased after the patient\u2019s wife was fully informed of the nature of the case report and the intention to publish the findings.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient or patient\u2019s next-of-kin for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no conflicts of interest to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"622"}}